Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of retinitis pigmentosa using engineered meganucleases

Treatment of retinitis pigmentosa using engineered meganucleases

US Patent 10603363 · Granted Mar 31, 2020

Estimated economic value: $7,023,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Genetically-modified T cells comprising a modified intron in the T cell receptor2025
Optimized engineered meganucleases having specificity for a recognition sequence2025
Rationally-designed single-chain meganucleases with non-palindromic recognition 2025
Rationally-designed single-chain meganucleases with non-palindromic recognition 2025
Methods for producing a complex transgenic trait locus2025
Methods for producing a complex transgenic trait locus2025
Polynucleotides encoding engineered meganucleases having specificity for recogni2024
Polynucleotides encoding engineered meganucleases having specificity for recogni2024
Polynucleotides encoding engineered meganucleases having specificity for recogni2024
Polynucleotides encoding engineered meganucleases having specificity for recogni2024
Engineered meganucleases that target human mitochondrial genomes2024
Optimized engineered nucleases having specificity for the human T cell receptor 2023